Directorate Change

RNS Number : 9203J
GeneMedix PLC
11 December 2008

11th December 2008

Reliance GeneMedix plc
(AIM: GMX)

Changes to the Board of Directors and name of Nominated Adviser

Reliance GeneMedix plc (the "Company"), the AIM listed biopharmaceutical company, which is part of the Reliance Life Sciences Group,
announces that the following changes to the Board of Directors have taken place with immediate effect:

Appointment of a new Non-Executive Director - Mr Dileep Choksi

Mr. Dileep C. Choksi, aged 59, is a Fellow Member of the Institute of Chartered Accountants of India * Rank holder, a Bachelor of Law, and a
Member of the Institute of the Cost and Works Accountants of India and has over 35 years of experience in the field of finance. Dileep is a
Non-Executive Director of several leading private companies, which are listed below. He has been an ex-visiting faculty member of the
Jamnalal Bajaj Institute of Management Studies, the Bankers Training College, and the Reserve Bank of India. He was also a trustee of Child
Relief and You (CRY), an organisation that is dedicated to the education and welfare of underprivileged children. Dileep was also the Vice
Chairman of Deloitte Haskins & Sells in India until his retirement in March 2008.

Mr. Choksi will be Chairman of the Audit Committee and a member of the Nomination and Remuneration committee. He fills the vacancy that was
created by the sudden death of Mr. Rajendra Lodha on 3 October 2008.

For the purposes of paragraph (g) of schedule 2 of the AIM rules Dileep C. Choksi holds or has held the following directorships and
partnerships over the last 5 years:

Current Directorships and Previous Directorships and Partnerships:
Partnerships:

ICICI Lombard General Insurance Co. Deloitte Haskins & Sells
Ltd
ICICI Prudential Asset Management
Co. Ltd
NSE.IT Limited
State Bank of India

The Company also confirms that Mr. Dileep Choksi has never:

* had any unspent convictions in relation to indictable offences; or
* been bankrupt or the subject of a voluntary arrangement, or had a receiver appointed to any of his assets; or
* been a director of any company which, while a director with an executive function or within 12 months after ceasing to be a
director with an executive function, had a receiver appointed or been into compulsory liquidation, creditors voluntary liquidation,
administration or company voluntary arrangements, or made any composition or arrangements with its creditors generally or with any class of
its creditors; or
* been a partner of any partnership, which while he was a partner or within 12 months after he ceased to be a partner, went into
compulsory liquidation, administration or partnership voluntary arrangement, or had a receiver appointed to any partnership asset; or
* had any public criticism by statutory or regulatory authorities (including recognised professional bodies); or
* been disqualified by a court from acting as a director or from acting in the management or conduct of affairs of any company.
The Company confirms that Mr. Dileep Choksi does not hold any shares in the Company.

Resignation of an Executive Director - Mr Gerhard Klement

Gerhard Klement provided his resignation to the Board on 10 November 2008 and the Board has now accepted this resignation.

The Board would like to extend its gratitude to the contribution made by Mr. Klement and wishes him well for the future.

Nominated Adviser

The Company also announces that, following the change of name and registered office of its nominated adviser, Deloitte Corporate Finance
is now a division of Deloitte LLP of 2 New Street Square, London, EC4A 3BZ.

ENQUIRIES:
Reliance GeneMedix plc Tel: +353 57 932 3572
Vinay Ranade, Chief Executive Officer

Deloitte Corporate Finance Tel: +44 (0)20 7936 3000
Jonathan Hinton, John Ball

Lothbury Financial Tel: +44 (0)20 7011 9411
Michael Padley, Louise Davis

This information is provided by RNS
The company news service from the London Stock Exchange

END

BOAURRBRWARUAAA

Grafico Azioni Reliance Genemedix (LSE:GMX)
Storico
Da Mag 2024 a Giu 2024